Skip to main navigation Skip to search Skip to main content

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

  • P. Schmid
  • , R. Salgado
  • , Y. H. Park
  • , E. Muñoz-Couselo
  • , S. B. Kim
  • , J. Sohn
  • , S. A. Im
  • , T. Foukakis
  • , S. Kuemmel
  • , R. Dent
  • , L. Yin
  • , A. Wang
  • , K. Tryfonidis
  • , V. Karantza
  • , J. Cortés
  • , S. Loi
  • Queen Mary University of London
  • University of Melbourne
  • Sungkyunkwan University
  • Vall d'Hebron Institute of Oncology
  • University of Ulsan
  • Yonsei University
  • Seoul National University
  • Karolinska Institutet
  • Medical Oncology
  • National Cancer Centre
  • Merck
  • Quiron Group

Research output: Contribution to journal › Article › peer-review

351   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science